Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: yosi s who wrote (618)	3/9/1999 12:12:00 AM
From: yosi s	Respond to of 1386

apnet.com About the Editor: George Fink Click here to view the complete list of the Editorial Board members. Dr. George Fink is Director of the Medical Research Council's Brain Metabolism Unit and Honorary Professor of the University of Edinburgh. A Fellow of the Royal Society of Edinburgh, Dr Fink graduated in medicine (MB BS) from Melbourne University, PhD from the University of Oxford where he worked as a Nuffield Dominions Scholar under the supervision of Geoffrey Harris, and was subsequently awarded the degree MD (Melbourne University) for his collected works. Dr Fink is a neuroendocrinologist who has retained a major interest in stress since the start of his career. His research in this area has focused on the neural control of the pituitary gland and the interactions between adrenal corticosteroids and the central stress neurohormones. Under his direction, the Brain Metabolism Unit has carried out extensive studies on the stress response in relation to mental disease, and especially the psychoses and Alzheimer's Dementia, and has recently discovered a novel intracellular signalling mechanism which plays a key role in corticosteroid negative feedback. Dr Fink's present research is focused on the way steroid hormones control central neurotransmission. He has published over 300 neuroendocrine papers and several books, of which "Neuroendocrine Molecular Biology", published in 1986, was hailed as a landmark in the field. Dr Fink was President of the European Neuroendocrine Association (1991-1995) and a member of the coordinating committee of the European Science Foundation Network on Neuroimmunomodulation, is a member of Council of the European Neuroscience Association, and has recently served as Chairman of the Assessment Panel for the European Union's Biomedicine Programme.